ASEAN targets medicine self-reliance, Malaysia proposes dashboard
The regional bloc aims to reduce reliance on imported medicines and external shocks, with Malaysia advocating for a real-time security dashboard and a three-month buffer stock model.
ASEAN strengthens pharmaceutical resilience
ASEAN governments are moving to reinforce medicine supply chains and expand domestic manufacturing capabilities, according to BMI, a unit of Fitch Solutions. This initiative aims to enhance the region's resilience against potential medicine shortages and disruptions from external supply shocks.
The push for greater pharmaceutical self-reliance comes as member states seek to secure critical medical supplies and stabilise healthcare systems across Southeast Asia. The strategy involves both improved monitoring and increased local production capacity.
Malaysia's proposals for regional security
Malaysia’s Ministry of Health is championing several measures to achieve these goals within ASEAN. Key among them is an ASEAN Medicines Security Dashboard, designed to offer real-time data on medicine prices, stock availability, supply chain distribution, and regional manufacturing capacity.
The Malaysian government also suggests its domestic policy of maintaining a three-month medicine buffer stock in government healthcare facilities could serve as a model for broader pharmaceutical preparedness across the bloc. These proposals seek to improve visibility and coordination.
Localisation efforts face long-term challenges
Despite growing political support for localising production, achieving significant pharmaceutical self-sufficiency remains a distant objective for ASEAN. Most member states still depend heavily on imported medicines, active pharmaceutical ingredients (APIs), and foreign technology, BMI noted.
Import dependence is particularly high in Malaysia, Thailand, and Vietnam, where foreign medicines account for approximately 42 per cent to 44 per cent of pharmaceutical sales. While countries like Vietnam target 80 per cent domestic production and Indonesia pursues broader independence, progress is likely to be gradual.
The drive for greater regional production will exert pressure on multinational drugmakers. To maintain market access in ASEAN, these companies will increasingly need to localise manufacturing operations, transfer technology, and engage in regional manufacturing partnerships.
However, limited research and development capabilities and underdeveloped innovation ecosystems across ASEAN will likely concentrate local production on generic medicines and formulations. This means the region will continue to rely on imported innovative therapies, creating a dual market for pharmaceutical firms.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.